Intech Investment Management LLC Has $983,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Intech Investment Management LLC raised its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 41.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,780 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,187 shares during the quarter. Intech Investment Management LLC owned about 0.08% of ANI Pharmaceuticals worth $983,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ANIP. US Bancorp DE lifted its stake in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV increased its holdings in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the period. HighTower Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth about $222,000. Finally, Hohimer Wealth Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth about $264,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock worth $191,776 in the last ninety days. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $64.26 on Friday. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -116.84 and a beta of 0.63. The firm’s 50 day simple moving average is $59.39 and its 200 day simple moving average is $58.13. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81.

Analysts Set New Price Targets

ANIP has been the topic of several analyst reports. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. Guggenheim upped their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.